Compare IT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | PRAX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.6B |
| IPO Year | 2010 | 2020 |
| Metric | IT | PRAX |
|---|---|---|
| Price | $158.41 | $327.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $270.44 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.2M | 375.4K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.65 | N/A |
| Revenue | ★ $2,021,441,000.00 | N/A |
| Revenue This Year | $3.75 | N/A |
| Revenue Next Year | $5.15 | $1,840.20 |
| P/E Ratio | $16.22 | ★ N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $139.18 | $26.70 |
| 52 Week High | $492.06 | $354.87 |
| Indicator | IT | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 53.37 |
| Support Level | $139.18 | $290.36 |
| Resistance Level | $164.47 | N/A |
| Average True Range (ATR) | 7.05 | 18.77 |
| MACD | 2.77 | -1.12 |
| Stochastic Oscillator | 70.48 | 55.40 |
Gartner provides independent research and analysis on information technology for chief information officers and other business executives who help plan companies' IT budgets. Its flagship Magic Quadrant reports inform many enterprises of their IT procurement decisions. Gartner also provides consulting services and holds some of the largest conferences in the IT industry. Around 80% of Gartner's revenue is generated from industry research.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.